Mr. Speaker, I would encourage that member not to prejudge the outcome of these negotiations.
Again, let me emphasize that our government has always sought to strike a balance between promoting innovation and ensuring that Canadians do have affordable drugs available. The prices charged for patented medicines sold in Canada are regulated by the Patented Medicine Prices Review Board. This will not change under a free trade agreement with the EU.
Our government continues to consult with the provinces and territories to ensure that the best interests of Canadians are reflected in the Canada-EU trade negotiations.